Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR4195661

—

c73c0c8f-5caa-57ac-8532-d19d07568d5c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.510
  • E2F_TARGETS+0.480
  • MYC_TARGETS_V2+0.420
  • MTORC1_SIGNALING+0.410
  • PROTEIN_SECRETION+0.390
  • UNFOLDED_PROTEIN_RESPONSE+0.380
  • G2M_CHECKPOINT+0.360
  • ANDROGEN_RESPONSE+0.310
  • XENOBIOTIC_METABOLISM+0.280
  • OXIDATIVE_PHOSPHORYLATION+0.270

Top 10 suppressed

  • MYOGENESIS-0.370
  • KRAS_SIGNALING_DN-0.250
  • P53_PATHWAY-0.230
  • WNT_BETA_CATENIN_SIGNALING-0.220
  • APICAL_JUNCTION-0.210
  • PANCREAS_BETA_CELLS-0.210
  • APICAL_SURFACE-0.190
  • INTERFERON_GAMMA_RESPONSE-0.180
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.130
  • IL6_JAK_STAT3_SIGNALING-0.130

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BS_M84H3KXA
medullo-epn-umap@date-based
MedMedulloblastoma0.807
2SJEPD030169_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.805
3SRR8518311
breast-umap@18
—E0.798
4SJEPD030367_D1.RNA-Seq
medullo-epn-umap@date-based
EPNAnaplastic EPN0.793
5d9eacc36-0ae3-41bd-aef6-503f91cb25aa
melanoma-umap@29
——0.789
6TCGA-78-7154-01A-11R-2039-07
lung-landscapes@6
—cohortA40.788
7SRR11296852
colon-landscapes@1
——0.785
8SRR975592
colon-landscapes@1
——0.785
9X11368e6c.aeb6.4de4.8e74.436b1cd1846c
lung-landscapes@6
—cohortA10.782
10BS_3BDAG9YN
brain-umap@2
medulloblastoma—0.781

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.510Inavolisib— uncovered
E2F_TARGETS0.480Inavolisib— uncovered
MYC_TARGETS_V20.420Idelalisib— uncovered
MTORC1_SIGNALING0.410Inavolisib— uncovered
PROTEIN_SECRETION0.390Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.380Idelalisib— uncovered
G2M_CHECKPOINT0.360Inavolisib— uncovered
ANDROGEN_RESPONSE0.310Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.280Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.270Remibrutinib— uncovered
GLYCOLYSIS0.190Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.190Inavolisib— uncovered
ANGIOGENESIS0.160Remibrutinib— uncovered
BILE_ACID_METABOLISM0.160Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.160Inavolisib— uncovered
KRAS_SIGNALING_UP0.150Inavolisib— uncovered
COAGULATION0.140Binimetinib— uncovered
MITOTIC_SPINDLE0.140Inavolisib— uncovered
FATTY_ACID_METABOLISM0.130Inavolisib— uncovered
PEROXISOME0.130Idelalisib— uncovered